March 28, 2022 -- NanoTemper Technologies has launched Spectral Shift technology within their Dianthus instrument, which the company said is built to handle the most challenging affinity-based screenings in drug discovery.
The development will aid in affinity-based screenings and drug discovery, which will alleviate challenges like targeting proteolysis-targeting chimeras, intrinsically disordered proteins, or fragment libraries, the company said.
NanoTemper's Dianthus instrument includes breakthrough Spectral Shift technology to handle the most challenging affinity-based screenings in drug discovery. Image courtesy of NanoTemper.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
